In comparison, lanifibranor, a pan-peroxisome proliferator-activated receptor (PPAR-α/δ/γ) agonist, achieved significant benefits on both NASH and fibrosis histology in a recent clinical phase 2b study (NATIVE trial)26. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.